News - Cellvizio - Mar 27, 2024

Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio

Paris, Boston, and London, March 27, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and V7, a leading AI and data labeling company, today announced their partnership to develop a cutting-edge infrastructure for AI applications with Cellvizio. 

Mauna Kea and V7 will collaborate to establish a strategic data repository of clinically-augmented, curated and annotated Cellvizio® images. This foundational data asset will spearhead Mauna Kea’s forthcoming AI-driven innovations, including: 

  • Future AI-based decision support applications for physicians, in oncology and immunology, benefiting from both in-house and collaborative developments with premier academic and industry partners; 
  • Foundational advanced digital biomarker models to expedite drug development, refine disease monitoring and improve the assessment of pathology states in the areas of cancer and food intolerance; and 
  • Continuous innovation catalyst, based on the actionable in-procedure data generated by Cellvizio®, to improve product usability and physician learning experience, or develop proactive maintenance strategies. 

The entire Mauna Kea Technologies ecosystem, from its partners to its customers, will benefit from this unique combined experience with V7 through the delivery of high-end, future-proof features. 

"We are thrilled with this partnership with V7, which marks an important step in our drive to harness the power of AI. It represents a major advancement in enriching Cellvizio's capabilities and benefits across a wide range of applications," said Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies. "By integrating V7's advanced AI platform with Mauna Kea's unique in vivo cellular imaging capabilities, our goal is to provide healthcare professionals with tools of unprecedented intelligence and precision. This synergy aims to transform diagnostic and treatment approaches, offering deeply impactful and personalized care solutions." 

Alberto Rizzoli, CEO of V7, concluded: "This partnership with Mauna Kea Technologies represents a significant leap forward in the application of AI within the healthcare sector. By combining our strengths, we are not just advancing the technology itself but also paving the way for a new era of medical diagnostics and treatment - which is why we founded the business back in 2018. Mauna Kea's Cellvizio platform provides an exceptional foundation for AI development, and we are excited to contribute our expertise to create truly transformative healthcare solutions."